(0) items in cart / view cart / checkout  
 
 
  Aerospace and Defense
  Automotive
  Chemicals
  Consumer Packaged Goods
  Energy and Utilities
  Financial Services
  Geography
  Government and Non-Profit Organisations
  Industrial Goods and Machinery
  Ingredients
  Knowledge Center
  Leisure and Arts
  Media
  Paper and Packaging
  Pharmaceuticals and Healthcare
  Retailing
  ServiceLine
  Technology and Communications
  Textiles
  Transport and Logistics
  Wholesale
 
Home >  Commercial Insight: HIV - Reshaping Treatment Paradigms

 
Commercial Insight: HIV - Reshaping Treatment Paradigms


Introduction

Detailed analysis of the antiretroviral therapy market. 10 year sales forecast for marketed drugs and key pipeline compounds, factoring in clinical trial results, new product launches and patent expiries.

Scope


In-depth analysis of the current HIV market across the major US and EU markets

Thorough assessment of underlying commercial and clinical factors shaping the antiretroviral market

Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets

Case study analysis of the entry inhibitor class focusing on the competitive environment and critical success factors


Highlights

By 2016 the HIV market is forecasted to grow to $11.5 billion. This growth will be driven mainly by the increase in numbers of patients accessing treatments as well as the launch of several new drugs and drug classes

The availability of several simple, once-daily treatments such as fixed dose combinations and once daily protease inhibitors has intensified the competition within the respective classes. Adherence to therapy is consequently expected to improve leading to a decline in the number of patients entering late-stage therapy.

The anticipated launches of pipeline antiretrovirals such as CCR5 inhibitors, integrase inhibitors and others, which demonstrate novel activity and efficacy against resistant mutants, will not only offer more variety to patients but will increase the overall value of the market.

Reasons to Purchase


Understand the constantly evolving market dynamics of antiretroviral drugs

Understand the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies

Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline antiretrovirals from 2006 to 2016.


     
  Published Price
07/11/2007
   $15200.00
   Free Shipping Worldwide

 
 
VPGDataMonitor.com © Copyright 2008. all rights reserved. Web Design by Spida Design